Tempo Fact Sheet

• Nanopharmaceuticals: A Revolutionary New Drug Technology
• NanoBiology: Tempo’s Unique, Next Generation Approach
• The Nanocell: Tempo’s First NanoBiology Platform
• Advancements Heralded in Nature
• Leadership

Nanopharmaceuticals: A Revolutionary New Drug Technology

Applying nanotechnology to pharmaceuticals represents a novel approach to designing drugs and enhancing their properties with the goal of creating improved therapies for fighting disease.

Nanopharmaceuticals are a new type of drug that consist of ultra-small particles containing drugs that are designed to enhance therapeutic utility. The unique properties of nanopharmaceuticals allow for the delivery of drugs to specific diseased tissues, the controlled release of therapeutic concentrations of drugs over a short or prolonged period of time and improved formulations of established therapies. The early developers of nanopharmaceuticals focused predominantly on reformulations that were aimed at overcoming a specific existing drug molecules’ most significant challenges, for example, toxicity and stability. More recent efforts have tailored nanopharmaceuticals to better target specific diseased tissues thereby increasing local concentrations of a particular drug molecule.

NanoBiology: Tempo’s Unique, Next Generation Approach

Within the field of nanopharmaceuticals, Tempo Pharmaceuticals is uniquely focused on an emerging field that we call NanoBiology – a next generation approach where an understanding of the complex biological microenvironment of human disease and disease processes is used in engineering nanoscale system that more optimally targets the root causes of disease.

At its core, NanoBiology combines deep biological knowledge and advances in engineering chemical structure at the nanoscale to create new breakthrough drugs that are intelligently designed to address the multiple processes that occur in diseased tissues. We believe with this unique, comprehensive approach we have the potential to achieve cures and improve the lives of patients where it was not previously possible.

Tempo is intelligently designing a deep pipeline of novel, NanoBiology-based drugs for oncology, rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, and other diseases. The Company was founded in 2006 and is located in Cambridge, Massachusetts.

The Nanocell: Tempo’s First NanoBiology Platform

An example of this unique NanoBiology focus is its first technological application, the Nanocell.

Licensed exclusively from the Massachusetts Institute of Technology, Tempo uses its proprietary Nanocell technology to develop multi-compartmental nanoparticle-based therapeutics in which two or more drugs with varied release times are packaged within the Nanocell, allowing for sequential delivery of the drugs, optimizing the location, time and combinatorial effect of two therapies while minimizing toxicities.

Advancements Heralded in Nature

The potential of the Nanocell technology was highlighted by preclinical data published in the journal Nature in July 2005. In the study, researchers designed a Nanocell that preferentially distributed to a cancerous tumor; the Nanocell then released a vascular targeting drug, leading to the collapse of the vascular network and trapping the nanoparticle within the tumor, followed by the subsequent release of a potent anti-tumor drug.
The data published in Nature showed that by concentrating and trapping the drugs in the tumor, the Nanocell dramatically inhibited tumor growth in mice and extended survival time compared to other drugs and drug combinations. Greater efficacy was observed when both drugs were delivered within the Nanocell compared to the individual drugs administered in combination, illustrating the advantage of using the Nanocell to deliver combinations of drugs. In addition, data on white blood cell counts in mice showed that the Nanocell format also provides a safety advantage compared to positive controls. Finally, data in the Nature paper demonstrated that the unique format of the Nanocell has the potential to overcome resistance mechanisms of cancer.

Based on these exciting and compelling data which demonstrate the potential to achieve unprecedented efficacy and safety, Tempo is working rapidly to complete additional preclinical studies with its own Nanocell oncology candidate and plans to enter human clinical trials in the near term.

Leadership

Tempo has assembled an all-star team consisting of management, founders, board of directors, investors, and scientific advisory board with proven expertise and success in building companies and developing and commercializing important products.

Management

• Alan Crane, Founder and CEO
• David Berstein, Senior Vice President and Chief Patent Council
• Tom Crawford, Ph.D., Senior Vice President, Pharmaceutical Sciences and Manufacturing
• Sandra Glucksmann, Ph.D., Founder and Senior Vice President, Research and Business Operations
• Mark Milton, Ph.D., Vice President, Nonclinical Development

Board of Directors

• Alan Crane, Founder and CEO Tempo Pharmaceuticals
• Robert Langer, Ph.D., Institute Professor, Massachusetts Institute of Technology
• Terry McGuire, Managing General Partner, Polaris Venture Partners
• Bryan Roberts, Ph.D., Managing General Partner, Venrock
• Ram Sasisekharan, Ph.D., Founder Tempo Pharmaceuticals and Professor, Massachusetts Institute of Technology
• Robert Tepper, M.D., Former President R&D, Millennium Pharmaceuticals

Scientific Advisors

• Roger Cohen, M.D., Director Phase I Clinical Program, Fox Chase Cancer Center
• Lee Ellis, M.D., Professor Surgical Oncology, MD Anderson
• Robert Langer, Ph.D., Institute Professor, Massachusetts Institute of Technology
• Ram Sasisekharan, Ph.D., Founder Tempo Pharmaceuticals, Professor, Massachusetts Institute of Technology
• Shiladitya Sengupta, Ph.D. Founder Tempo Pharmaceuticals, Assistant Professor, Harvard Medical School
• Robert Tepper, M.D., Former President R&D, Millennium Pharmaceuticals
• Daniel Von Hoff, M.D., Director Clinical Translation, Arizona Health Center
• Bruce Zetter, Ph.D., Chairman SAB, Professor Harvard and CSO Children’s Hospital, Boston